JHP Pharmaceuticals has entered into an agreement with an undisclosed pharmaceutical company to produce supplies of a lyophilized biologic for international, late-phase clinical trials. Stuart Hinchen, JHP’s president and chief executive officer, commented, “We know that customers want to seamlessly progress from clinical batch production to product launch and then commercialization. JHP’s established infrastructure and expertise transitioning products from clinical to commerc...